Save information for later
Sign Up

Learn About Allan-Herndon-Dudley Syndrome

What is the definition of Allan-Herndon-Dudley Syndrome?

Allan-Herndon-Dudley syndrome is a rare disorder of brain development that causes moderate to severe intellectual disability and problems with movement. This condition, which occurs exclusively in males, disrupts development from before birth. Although affected males have impaired speech and a limited ability to communicate, they seem to enjoy interaction with other people.

What are the causes of Allan-Herndon-Dudley Syndrome?

Mutations in the SLC16A2 gene cause Allan-Herndon-Dudley syndrome. The SLC16A2 gene, also known as MCT8, provides instructions for making a protein that plays a critical role in the development of the nervous system. This protein transports a particular hormone into nerve cells in the developing brain. This hormone, called triiodothyronine or T3, is produced by a butterfly-shaped gland in the lower neck called the thyroid. T3 appears to be critical for the normal formation and growth of nerve cells, as well as the development of junctions between nerve cells (synapses) where cell-to-cell communication occurs. T3 and other forms of thyroid hormone also help regulate the development of other organs and control the rate of chemical reactions in the body (metabolism).

How prevalent is Allan-Herndon-Dudley Syndrome?

Allan-Herndon-Dudley syndrome appears to be a rare disorder. About 25 families with individuals affected by this condition have been reported worldwide.

Is Allan-Herndon-Dudley Syndrome an inherited disorder?

This condition is inherited in an X-linked recessive pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top Allan-Herndon-Dudley Syndrome Local Doctors?
Elite in Allan-Herndon-Dudley Syndrome
Elite in Allan-Herndon-Dudley Syndrome
Essen, NW, DE 

Heike Heuer practices in Essen, Germany. Ms. Heuer is rated as an Elite expert by MediFind in the treatment of Allan-Herndon-Dudley Syndrome. Her top areas of expertise are Allan-Herndon-Dudley Syndrome, Hypotonia, Hypothyroidism, and Muscle Atrophy.

Elite in Allan-Herndon-Dudley Syndrome
Elite in Allan-Herndon-Dudley Syndrome
Bonn, NW, DE 

Ulrich Schweizer practices in Bonn, Germany. Mr. Schweizer is rated as an Elite expert by MediFind in the treatment of Allan-Herndon-Dudley Syndrome. His top areas of expertise are Allan-Herndon-Dudley Syndrome, Thyroid Hormone Plasma Membrane Transport Defect, Hypotonia, and Muscle Atrophy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Allan-Herndon-Dudley Syndrome
Elite in Allan-Herndon-Dudley Syndrome
Bonn, NW, DE 

Doreen Braun practices in Bonn, Germany. Ms. Braun is rated as an Elite expert by MediFind in the treatment of Allan-Herndon-Dudley Syndrome. Her top areas of expertise are Allan-Herndon-Dudley Syndrome, Hypotonia, Thyroid Hormone Plasma Membrane Transport Defect, and Muscle Atrophy.

What are the latest Allan-Herndon-Dudley Syndrome Clinical Trials?
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): a Double-blind, Randomized, Placebo-controlled Study

Summary: This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total triio...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

Summary: The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepo...

Who are the sources who wrote this article ?

Published Date: April 01, 2013
Published By: National Institutes of Health

What are the Latest Advances for Allan-Herndon-Dudley Syndrome?